Family run life sciences developer and investor Gen Two is to deliver a 125,000 sq ft research and development hub in Cambridge.
The firm has been given the go-ahead by South Cambridge District Council for the redevelopment of a 5.2-acre former brownfield site in Fowlmere.
It plans to retain and reuse two of the five existing two-storey buildings located on site to provide flexible labs and offices. The scheme, known as Alchemy, will comprise eight self-contained laboratory suites ranging in size from 10,000 sq ft to 20,000 sq ft which could be combined to provide larger headquarter facilities.
The developer has also upgraded power to the site to target biotech occupiers and scale-up companies focused on the full spectrum of R&D.
Construction is expected to begin in the first half of 2024.
The scheme is aiming to secure BREEAM Excellent certification upon completion.
Ariel Levy, co-founder of Gen Two, said: “In the Cambridge life sciences ecosystem there is a need for additional fit-for-purpose and adaptable R&D scale-up space, which we are proud to have secured planning consent for.”
Daniel Sterling, co-founder of Gen Two, added: “We’ve spent the past few years assembling an experienced team of experts with a vision to build an institutional-grade portfolio of life sciences real estate assets in Cambridge, Oxford and Leeds.
“As we look to grow our portfolio in these places and bring forward our existing pipeline, we are extremely encouraged by the number of meaningful conversations we are having with best-in-class capital partners, who also see the highly supportive long-term fundamentals for high quality and flexible life sciences spaces.”
To send feedback, e-mail evelina.grecenko@eg.co.uk or tweet @Gre_Eve or @EGPropertyNews
